AI English summary of an SEC filing — figures as filed
Viatris VTRSThe company said the Board increased the number of directors from 12 to 14 on May 5, 2025 and appointed Frank D’Amelio and Michael Severino as independent directors, effective immediately, with terms expiring at the 2025 Annual Meeting.
Key points
AI summaryThe company said the Board increased the number of directors from 12 to 14 on May 5, 2025 and appointed Frank D’Amelio and Michael Severino as independent directors, effective immediately, with terms expiring at the 2025 Annual Meeting.
The company said it assigned D’Amelio to the Finance Committee and Severino to the Science and Technology Committee. The two will receive compensation consistent with the company’s other non-employee directors, and the company has entered into an indemnification agreement with each of them.
The company said Rajiv Malik and Harry Korman notified it on May 5, 2025 that they will not stand for re-election at the 2025 Annual Meeting and will retire from the Board at the end of their current terms. The company said the retirements did not result from any disagreement with the company.
The company said in its press release that D’Amelio has 20 years of experience as a public company CFO and served as CFO at Pfizer for 15 years. It also described Severino as Chief Executive Officer of Tessera Therapeutics, Inc. and a former Vice Chairman and President of AbbVie Inc.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Board Expands to 14 Directors from 12, Adds 2 Independent Directors
The company said the Board increased the number of directors from 12 to 14 on May 5, 2025 and appointed Frank D’Amelio and Michael Severino as independent directors, effective immediately, with terms expiring at the 2025 Annual Meeting.
Source · Based on the filing body and exhibits
Committee Assignments, Compensation and Indemnification for New Directors
The company said it assigned D’Amelio to the Finance Committee and Severino to the Science and Technology Committee. The two will receive compensation consistent with the company’s other non-employee directors, and the company has entered into an indemnification agreement with each of them.
Source · Based on the filing body and exhibits
Rajiv Malik and Harry Korman Notify Intent to Retire From Board
The company said Rajiv Malik and Harry Korman notified it on May 5, 2025 that they will not stand for re-election at the 2025 Annual Meeting and will retire from the Board at the end of their current terms. The company said the retirements did not result from any disagreement with the company.
Source · Based on the filing body and exhibits
Backgrounds of New Directors
The company said in its press release that D’Amelio has 20 years of experience as a public company CFO and served as CFO at Pfizer for 15 years. It also described Severino as Chief Executive Officer of Tessera Therapeutics, Inc. and a former Vice Chairman and President of AbbVie Inc.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…